Spun out of University of Louisville, Koligo Therapeutics has already launched its first cell therapy product and aims to commercialise a treatment for covid-19.

Koligo Therapeutics, a US-based cell therapy developer aligned to University of Louisville, has been acquired by personalised drug producer Orgenesis for about $15m in stock. The deal will consist of approximately 2.1 million common shares each priced at $7.00, and Orgenesis will also assume $1.3m of Koligo’s debt. Launched in 2016, Koligo focuses on cell…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.